Ultralight-sensitive neuro-opsin-based optogenetic tools for Gq-coupled signaling and / or cell activation

Isolated light-sensitive opsins like cOpn5 provide a solution to the limitations of existing optogenetic tools by offering high photosensitivity and rapid, precise activation of Gq-coupled signaling and cell activation, facilitating the study of physiological and behavioral functions in various species.

JP2024545368APending Publication Date: 2024-12-05GENANS BIOTECHNOLOGY CO LTD

Patent Information

Application Number
JP2024558169
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-20
Filing Date
2022-12-20
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Existing optogenetic tools for Gq-coupled signaling and cell activation face limitations in photosensitivity and reaction kinetics, and have not been widely used due to these constraints.

Method used

Development of isolated light-sensitive opsins, particularly Opn5 orthologs such as cOpn5, which are hypersensitive to blue light, allowing rapid and precise activation of signal transduction and cell activation without the need for exogenous retinal, and can be used in various animal species including birds, reptiles, amphibians, and fish.

Benefits of technology

cOpn5 demonstrates high photosensitivity, rapid response times, and precise spatial control, effectively mediating ATP release and neuronal activation in vivo, enabling the study of physiological and behavioral functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545368000028
    Figure 2024545368000028
  • Figure 2024545368000029
    Figure 2024545368000029
  • Figure 2024545368000030
    Figure 2024545368000030
Patent Text Reader

Abstract

The present invention is q The present invention relates to isolated light-sensitive opsins for rapid, reversible and precise activation of signals and / or cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] G protein-coupled receptors (GPCRs) regulate many intracellular signaling pathways and represent some of the most intensively studied drug target points (Hauser et al., 2017). After ligand binding, GPCRs undergo a conformational change and transmit it to heterotrimeric G proteins, which then convert the G α G tightly bound to the subunit βγ It is a multisubunit complex containing the heterotrimeric G α The G subfamily of subunits q The proteins couple to a class of GPCRs and mediate cellular responses to neurotransmitters, sensory stimuli and hormones throughout the body. Their main downstream signaling target points include the phospholipase Cβ (PLC-β) enzyme, which catalyzes the hydrolysis of the phospholipid phosphatidylinositol diphosphate (PIP2) to inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 is released from intracellular stored Ca 2+ into the cytoplasm, causing Ca 2+ G activates protein kinase C (PKC) together with DAG. q Coupled GPCRs and intracellular Ca 2+ To study the signaling mechanisms and physiological functions of release, we developed several tools, including chemical genetics and photoactivatable small molecules.

[0002] Optogenetics utilizes light-responsive proteins to achieve optically controlled perturbation of cellular activity with genetic specificity and high spatiotemporal precision. Since the early discovery of optogenetic tools using light-sensitive ion channels and transporters, a variety of techniques have been developed that now support optical intervention in intracellular second messengers, protein interactions and degradation, as well as gene transcription. Creatively designed G q The coupled rhodopsin-GPCR chimera Opt-a1AR increased intracellular Ca in response to prolonged light stimulation (60 s). 2+It can induce an increase in the amount of opsin produced by the retinal nucleus (Airan et al., 2009). However, such tools have not been widely used, probably due to limitations related to light sensitivity and kinetics (Tichy et al., 2019). Most animals detect light using GPCR-based photoreceptors, where the photoreceptor contains a protein moiety (opsin) and a vitamin A derivative (retinal) that functions as both ligand and chromophore. Thousands of opsins have been identified so far. Two recent studies have demonstrated the use of GPCRs from mosquitoes and lampreys in the inhibition of presynaptic terminals of neurons. i The use of G-based opsins has been reported and it is readily demonstrated that certain naturally occurring photoreceptors are suitable for use as efficient optogenetic tools. q Regarding signal transduction, melanin (Opn4) in a subpopulation of mammalian retinal ganglion cells is a G q Opn4 is a conjugated opsin that mediates non-image-forming visual functions. However, HEK293 or Neuro-2a cells heterologously expressing Opn4 show weak light responses and require additional retinal in the medium. Opn5 (neuropsin) and its orthologues in many vertebrates are G i It has been reported that the opsin is ultraviolet (UV)-sensitive and protein-coupled. Summary of the Invention [Problem to be solved by the invention]

[0003] The present invention is q The present invention relates to isolated light-sensitive opsins for rapid, reversible and precise activation of signals and / or cells.

[0004] In a first aspect, the present invention provides a method for the preparation of a medicament for the treatment of a cancer, comprising: q The present invention relates to isolated light-sensitive opsins that are used for signal transduction and / or cell activation.

[0005] In some embodiments, the light has a wavelength in the range of 360 to 520 nm, preferably 450 to 500, and more preferably 460 to 480 nm.

[0006] In some embodiments, the isolated opsin is an isolated opsin, a homolog thereof, an ortholog thereof, a paralog thereof, a fragment or a variant thereof, derived from an organism, q It has signal transduction and / or cell activation activity.

[0007] In some embodiments, the isolated opsin has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a wild-type opsin, a homolog thereof, an ortholog thereof, a paralog thereof, a fragment or a variant thereof in the organism, and is G q It has signal transduction and / or cell activation activity.

[0008] In some embodiments, the organism is an animal.

[0009] In some embodiments, the isolated opsin is an isolated opsin 5 (Opn5) from an animal, a homolog thereof, an ortholog thereof, a paralog thereof, a fragment thereof, or a variant thereof, q It has signal transduction and / or cell activation activity.

[0010] In some embodiments, the isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a wild-type opsin 5 (Opn5), a homolog thereof, an ortholog thereof, a paralog thereof, a fragment or a variant thereof in the animal, and q It has signal transduction and / or cell activation activity.

[0011] In some embodiments, the animal is a vertebrate.

[0012] In some embodiments, the animal is a bird, reptile or fish, amphibian or mammal.

[0013] In some embodiments, the animal is a bird, including, but not limited to, chicken, duck, goose, ostrich, emu, rhea, kiwi, cassowary, turkey, quail, chicken, falconry, hawk, falcon, pigeon, parakeet, crowned cockatoo, macaw, parrot, passerine (e.g., songbird), jay, blackbird, finch, warbler, and sparrow.

[0014] In some embodiments, the animal is a reptile, including, but not limited to, a lizard, a snake, an alligator, a sea turtle, a crocodile, and a tortoise.

[0015] In some embodiments, the animal is a fish, including but not limited to catfish, eels, sharks, and swordfish.

[0016] In some embodiments, the animal is an amphibian, including but not limited to toads, frogs, newts, and salamanders.

[0017] In some embodiments, the isolated Opsin 5 (Opn5) is an isolated wild-type Opsin 5 (Opn5) from a chicken or a fragment or variant thereof, q It has signal transduction and / or cell activation activity.

[0018] In some embodiments, the isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to wild-type opsin 5 (Opn5) from the chicken, andq It has signal transduction and / or cell activation activity.

[0019] In some embodiments, the isolated Opsin 5 (Opn5) is an isolated wild-type Opsin 5 (Opn5) from a sea turtle or a fragment or variant thereof, q It has signal transduction and / or cell activation activity.

[0020] In some embodiments, the isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to wild-type opsin 5 (Opn5) from the sea turtle, and q It has signal transduction and / or cell activation activity.

[0021] In some embodiments, the isolated opsin 5 (Opn5) has the amino acid sequence set forth in SEQ ID NO:1 (cOpn5) or a fragment or variant thereof, q It has signal transduction and / or cell activation activity.

[0022] In some embodiments, the isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence set forth in SEQ ID NO:1 (cOpn5), and is q It has signal transduction and / or cell activation activity.

[0023] In some embodiments, the isolated opsin 5 (Opn5) has the amino acid sequence set forth in SEQ ID NO:2 (tOpn5) or a fragment or variant thereof, and q It has signal transduction and / or cell activation activity.

[0024] In some embodiments, the isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence set forth in SEQ ID NO:2 (tOpn5), and is q It has signal transduction and / or cell activation activity.

[0025] The isolated opsin 5 (Opn5) is an intracellular G q It can be used as a convenient optogenetic tool to precisely activate signaling and / or cells.

[0026] In a second aspect, the present invention relates to an isolated nucleic acid encoding the isolated opsin according to the first aspect.

[0027] In some embodiments, the isolated nucleic acid encodes a wild-type opsin in an organism, a homolog thereof, an ortholog thereof, a paralog thereof, a fragment thereof, or a mutant thereof, q It has signal transduction and / or cell activation activity.

[0028] In a third aspect, the present invention relates to a chimeric gene comprising the isolated nucleic acid sequence according to the second aspect, said nucleic acid sequence being operably linked to suitable regulatory sequences.

[0029] In a fourth aspect, the present invention relates to a vector comprising the isolated nucleic acid according to the second aspect or the chimeric gene according to the third aspect.

[0030] The vector may be a eukaryotic vector, a prokaryotic expression vector, a viral vector or a yeast vector.

[0031] In some embodiments, the vector is a herpes simplex virus vector, a vaccinia virus vector, or an adenovirus vector, an adeno-associated virus vector, a retrovirus vector, or an insect vector.

[0032] Preferably, the vector is recombinant AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVS, AAVO or AAV10.

[0033] In some embodiments, the vector is an expression vector.

[0034] In some embodiments, the vector is a gene therapy vector.

[0035] In a fifth aspect, the present invention relates to an isolated cell or cell culture comprising an isolated nucleic acid according to the second aspect, a chimeric gene according to the third aspect or a vector according to the fourth aspect.

[0036] For example, expression of cOpn5 in HEK293T cells prevents the release of G from intracellular accumulations induced by blue light. q Dependent Ca 2+ It potently mediates an increase in

[0037] For example, optogenetic activation of cOpn5-expressing astrocytes in the mouse brain induces massive ATP release.

[0038] In a sixth aspect, the present invention provides a method for the preparation of a medicament for the treatment of cancer, comprising: q A disease or condition mediated by signal transduction and / or cell activation, or q The present invention relates to the use of an isolated opsin according to the first aspect, an isolated nucleic acid according to the second aspect, a chimeric gene according to the third aspect, a vector according to the fourth aspect or an isolated cell or cell culture according to the fifth aspect in the treatment of a disease or condition involving signal transduction and / or cell activation.

[0039] cOpn5-mediated optogenetics can be used to activate neurons and control animal behavior in a circuit-dependent manner.

[0040] In a seventh aspect, the present invention provides a method for determining whether G q A disease or condition mediated by signal transduction and / or cell activation, or G q A method of treating a disease or condition involving signal transduction and / or cellular activation, said method comprising administering an isolated opsin according to the first aspect, an isolated nucleic acid according to the second aspect, a chimeric gene according to the third aspect, a vector according to the fourth aspect or an isolated cell or cell culture according to the fifth aspect.

[0041] In some embodiments, the G q A disease or condition mediated by signal transduction and / or cell activation, or q Diseases or conditions involving signal transduction and / or cell activation are q These include, but are not limited to, diseases or conditions that benefit from signal transduction and / or cell activation, for example, those that benefit from astrocyte activation, enhanced ATP release, or increased neuronal activity.

[0042] In some embodiments, the G q A disease or condition mediated by signal transduction and / or cell activation, or q Diseases or conditions involving signal transduction and / or cell activation include, but are not limited to, diseases or conditions that would benefit from activated cells such as pancreatic islet cells, immune cells, neuronal cells, e.g., central neurons, astrocytes, glial cells, muscle cells, skeletal cells, endothelial cells, epithelial cells, nervous system cells, skin cells, lung cells, kidney cells, and liver cells, cardiomyocytes, or vascular endothelial cells.

[0043] In some embodiments, the disease or condition includes, but is not limited to, diabetes, immunosuppressive diseases, Alzheimer's disease, depression, anxiety, cerebral hemorrhage, and the like.

[0044] In some embodiments, the method comprises applying blue light having a wavelength in the range of 360-550 nm, preferably 450-500, more preferably 460-480 nm.

[0045] In some embodiments, the method further comprises performing two-photon activation using long wavelength (≧920 nm) light.

[0046] The isolated opsins described in the present invention are photosensitive to wavelengths in the range of 360-550 nm, preferably 450-500, and more preferably 460-480 nm. Specifically, blue light at 470 nm is the strongest Ca receptor in cells. 2+ A transient was evoked, which means that the isolated opsin described in this invention is hypersensitive to light of 470 nm wavelength.

[0047] The present invention includes all combinations of specific embodiments described herein. [Brief description of the drawings]

[0048] [Figure 1] We show that cOpn5 in HEK 293T cells mediates robust activation of light-induced Gq signaling. [Diagram 2] We show that cOpn5 couples to Gq but not Gi signaling. [Diagram 3] We show that cOpn5 mediates sensitive optical control of Gq signaling with high spatiotemporal resolution. [Figure 4] 1 shows that cOpn5 mediates a more rapid and sensitive response to light than opto-a1AR, hM3Dq or opn4. [Diagram 5] We show that cOpn5 efficiently mediates astrocyte activation. [Figure 6] We show that cOpn5-mediated astrocyte activation induces a massive ATP flush and neuronal activation in vivo. [Figure 7] We show that cOpn5 mediates sustained and robust ATP release in astrocytes and activation of peripheral neurons. [Figure 8] We show that cOpn5-mediated optogenetics alters mouse behavior in a neural circuit-dependent manner. [Figure 9] We show that cOpn5-mediated optogenetics reliably activates neurons. [Figure 10] The injection location and arrangement of the optical fiber are shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0049] In this study, we tested the ability of opsins from multiple species, particularly Opn5 orthologues, to mediate light-induced G q It has been discovered that these antibodies sensitively and potently mediate signal transduction and / or cell activation.

[0050] Preferably, said Opn5 orthologue is the chicken orthologue (abbreviated as cOpn5) or the sea turtle orthologue (abbreviated as tOpn5).

[0051] Detailed characterization of Opn5, and especially cOpn5, revealed that it is hypersensitive to blue light (μW / mm 2 Level, existing G q Conjugated opsin-based tools opto-a1AR and opn4 have ~3 orders of magnitude higher sensitivity, high temporal (responds to 10 ms light pulses, ~3 orders of magnitude faster than opto-a1AR or opn4) and spatial (subcell level) resolution, and do not require the addition of chromophores. Specifically, endogenous retinal is sufficient and no additional retinal is required.

[0052] The present invention further demonstrates that cOpn5 optogenetics can be used as an efficient method to activate astrocytes in vivo to induce massive ATP release and to activate neurons to produce robust behavioral changes in freely moving mice. These findings suggest that cOpn5, and possibly other Opn5 orthologues, can be used as a powerful optogenetic tool to enhance GTPase activity in both non-excitable and excitable cells. q Support experimental investigations of physiological and behavioral functions associated with signal transduction and / or cell activation.

[0053] cOpn5 is G q Mediating optogenetic activation of signal transduction and / or activation of cells Specifically, we tested Opn5 orthologues from chicken, sea turtle, human and mouse (which share 80-90% protein sequence identity with each other) and found that they suppress blue light-induced G signaling in HEK 293T cells. q The cells are tested to determine whether they have the ability to mediate signal transduction activation. Blue light is used as the stimulus, and the red intracellular calcium indicator Calbryte TM Monitoring relative Ca using 630AM dye 2+ The Opn5 orthologues from chicken (cOpn5) and sea turtle (tOpn5) respond to Ca 2+ cOpn5 mediates an immediate and strong light-induced increase in signal transduction (~3ΔF / F) whereas no light effect is observed in cells expressing human or mouse Opn5 orthologues. As exemplified with the chicken orthologue, cOpn5 colocalizes with the EGFP-CAAX membrane marker, indicating that it is efficiently transported to the plasma membrane. There is no need to add exogenous retinal to the medium, suggesting that endogenous retinal is sufficient to enable cOpn5 to function. Ca 2+ The signal is extracellular Ca 2+ This is because the Ca2+ receptor is resistant to removal from intracellular stores. 2+ In both cOpn5-expressing cells, Gq Protein inhibitors (e.g., YM-254890, highly selective G q Preincubation of the α-CaCl2+ protein inhibitor inhibits light-induced Ca 2+ In cells expressing cOpn5 but not human OPN5, a light-induced increase in the levels of inositol phosphate (IP1), a rapid degradation product of IP3, was detected, and furthermore, treatment with YM-254890 reduced the magnitude of such an increase. In cOpn5-expressing cells (e.g., HEK293T cells), blue light also triggers phosphorylation of MARCKS protein (a putative PKC target point) in a PKC activity-dependent manner. In contrast, in the presence of retinal, blue light irradiation efficiently reduces cAMP levels in cells expressing human and mouse Opn5, but in the absence of retinal, blue light irradiation has no such effect in cells expressing cOpn5. Taken together, these data suggest that blue light irradiation reduces the levels of cOpn5 and G in HEK293T cells. q This supports the idea that it enables coupling with signal transduction pathways.

[0054] cOpn5-mediated optogenetics is sensitive and precise Specifically, the present invention characterizes the light-activation properties of cOpn5. cOpn5 can be heterologously expressed in cells (e.g., HEK293T cells). Opn5 has previously been thought to be an ultraviolet (UV)-sensitive photoreceptor, but it is not yet fully understood to be a photoreceptor that is sensitive to light at a fixed light intensity (100 μW / mm 2 ) plotting a series of wavelengths in the range of 365-630 nm, blue light at 470 nm is the most intense Ca 2+ We show that cOpn5 induces a transient, whereas UVA light (365 and 395 nm) is less efficient and longer wavelength visible light (561 nm or longer) has no effect at all. We tested the effect of various light durations on cOpn5-expressing HEK293T cells, using short light pulses (1, 5, 10, 20, 50 ms, 16 μW / mm 2 , 470 nm) stimulated Ca when the light duration exceeded 10 ms. 2+ This shows that the response reaches the saturated mode.2 , 470 nm), even with prolonged light duration, the Ca 2+ Without further increasing the signal amplitude, we found that illumination with 470 nm light at different intensities showed that ~4.8 μW / mm and 16 μW / mm blue light produced approximately half-maximal and maximal responses, respectively. These data indicate that the light sensitivity of cOpn5 is 2-3 orders of magnitude higher than reported values ​​for channelrhodopsin-2 (ChR2), a common optogenetic tool. Taken together, our results demonstrate that cOpn5 can function as a single-component optogenetic tool without the addition of retinal, that cOpn5 is ultrasensitive to blue light, and that low light intensities (16 μW / mm) are required for its full activation. 2 ) and short duration (10 ms) are required.

[0055] The performance of cOpn5 was compared with that of opto-a1AR, which binds rhodopsin to G q A chimeric GPCR engineered by mixing with an opto-α1AR-coupled adrenergic receptor. We followed previously reported protocols to measure slow and small (~0.5ΔF / F) Ca in opto-α1AR-expressing HEK293T cells. 2+ To induce a signal increase, very long and intense irradiation (60 s, 7 mW / mm 2 ) is required, and 15 seconds of exposure is ineffective. The performance of cOpn5 is compared with that of opn4, and opn4 is q A natural opsin that has been reported to be a tool for signal transduction activation. Slow (~1ΔF / F) Ca in opn4-expressing HEK293T cells 2+ To induce a signal increase, strong irradiation (25 s, 40 mW / mm 2 ) and additional retinal are required. Thus, compared to existing opsin-based tools (opto-a1AR and opn4), cOpn5 is much more light sensitive (~3 orders of magnitude more sensitive), requires much shorter exposure times (10 ms vs. 60 s), and generates a stronger response.

[0056] Furthermore, we compared the performance of cOpn5 with that of a general G q We compare the performance of the coupled chemical genetics tool hM3Dq, where hM3Dq is activated by the addition of the exogenous small molecule ligand clozapine-N-oxide (CNO). Light-induced activation of cOpn5-expressing HEK293T cells and CNO-induced activation of hM3Dq-expressing HEK293T cells show similar Ca 2+ The peak response amplitude of the signal. At the same time, compared with hM3Dq-expressing HEK293T cells, cOpn5-expressing HEK293T cells show faster and more temporally precise responses and faster recovery times. These results indicate that cOpn5-mediated optogenetics is more controllable in terms of temporal precision than hM3Dq.

[0057] cOpn5 optogenetics allows precise spatial control of cellular activity. Brief light stimulation (63 ms) restricted to subcellular regions of individual cOpn5-expressing HEK293T cells results in immediate activation of individual cells. Interestingly, in highly confluent regions, Ca 2+ The signal propagates to surrounding cells, thereby suggesting intercellular communication between HEK293T cells by a yet unidentified mechanism. cOpn5 is expressed using an AAV vector for bicistronic expression of cOpn5 and EGFP marker proteins in primary astrocyte cultures prepared from neonatal mouse brains. Ca was detected using Calbryte 630 AM dye. 2+ We monitored the Ca levels and found that illumination of cOpn5-expressing astrocytes with blue light induced a strong Ca 2+ When light stimulation (63 ms) was precisely restricted to the subcellular region of an individual cOpn5-expressing astrocyte, a Ca transient (~8ΔF / F) was observed. 2+ We observe that the signal is propagated within individual cells. Similar to the study in HEK293T cells, Ca signals are transmitted from stimulated astrocytes to more distal unstimulated astrocytes. 2+A gentle wave-like propagation of the signal is observed. Thus, these experiments confirm that precise spatial control is possible with cOpn5 optogenetics and suggest that it may be useful to study the dynamics of the astrocytic networks we first discovered using neurochemical and mechanical stimulation.

[0058] cOpn5 optogenetic activation of astrocytes induces massive ATP release and neuronal activation in vivo We test the in vivo performance of cOpn5-mediated optogenetics. Astrocytes represent an important population of non-excitable cells in the central nervous system, where optogenetic tools have so far met with limited success. ATP is known to be a communication messenger between astrocytes, but the response of intracellular Ca to ATP release is poorly understood. 2+ The real-time effects of ATP have yet to be visualized. The recently reported GPCR activation-based ultrasensitive ATP sensor GRAB ATP We use this technique to monitor changes in extracellular ATP levels. Specifically, we monitored the expression of cOpn5 and GRAB in mouse S1 sensory cortex after injection of AAV vectors containing the GfaABC1D promoter (commonly used to drive gene expression in astrocytes). ATP Expresses a sensor.

[0059] GRAB from head-fixed, awake, normally behaving mice ATP The signal is then imaged using two-photon imaging. Surprisingly, the 920 nm light delivered for imaging itself does not interfere with cOpn5 and GRAB signaling. ATP Blue light pulses induce massive ATP flashes in mice expressing cOps5 but not in mice expressing the ATP sensor but lacking cOps5 expression. No blue light pulse is required to stimulate ATP signals. Individual ATP flashes are typically in the range of 20–100 μm in diameter and last for ∼1 min. After an initial quiescent period of ∼1 min, the flash frequency gradually increases, reaching a peak value within ∼5 min and expanding beyond the imaging area (640 × 640 μm). 2) reaches a level of ~50 flashes / min. Furthermore, with repeated testing, high frequency ATP flashes also occur. ATP In mice expressing only Opn5, sporadic ATP events (~0.3 flashes / min within the imaging field) were observed, whereas 8 h after proinflammatory treatment with intraperitoneal injection of lipopolysaccharide (LPS), ATP flash events increased almost 6-fold above basal conditions (~2 flashes / min) but showed a fairly stable frequency, confirming that inflammation induces ATP release in the brain. Given that the ATP flash frequency observed in cOpn5-expressing mice is ~25-fold higher than the flash frequency after proinflammatory treatment in mice not expressing Opn5, we demonstrate that cOpn5-mediated photoactivation of astrocytes induces continuous and massive ATP release in vivo.

[0060] Astrocytes release ATP and other gliotransmitters acting on neuronal receptors to regulate neuronal activity. Using cOpn5-mediated astrocyte activation, we investigated the effects of cOpn5 on neuronal Ca in head-fixed, awake, normally behaving mice. 2+ Two-photon imaging of the signal. cOpn5-expressing cells (n=406) colocalize with GFAP staining (n=397) but not with GCaMP7b-expressing neurons. Raw tracking example and cohort data show that cOpn5-mediated astrocyte activation significantly increases neuronal activity for 15-20 min compared to 0-5 min. cOpn5 is strictly expressed in astrocytes, which is confirmed by the colocalization of cOpn5-expressing cells and GFAP staining signals (different from GCaMP7b signals in neurons). It is demonstrated that cOpn5-mediated astrocyte photoactivation increases peripheral neuronal activity in vivo. Furthermore, the present invention shows that the long-wavelength (920 nm) light of the pulsed laser used for two-photon imaging can activate cOpn5, suggesting that cOpn5 may have two-photon optogenetic potential.

[0061] cOpn5 optogenetics to activate neurons and regulate animal behavior We will investigate the application of cOpn5-mediated optogenetics in neurons. First, we will show that cOpn5 regulates light-induced Ca 2+ We used AAV and the pan-neuronal SYN promoter to express cOpn5 and genetically encoded Ca signals in mouse cortical neurons. 2+ In the brain slice samples, a blue light pulse (10 s, 100 μW / mm 2 , 473 nm) to measure Ca in neurons. 2+ cOpn5 robustly evokes light-induced transients (Figure 8b, c). Thus, cOpn5 can also mediate light-induced activation in neurons.

[0062] We study the effects of light-induced cOpn5 activation on the electrophysiological properties of neurons in slice samples from the motor cortex, hippocampus and dorsal striatum (Figure 8d). Two types of activation patterns are observed. In most recorded neurons, blue light pulses induce small depolarizing currents (~20 pA) in voltage clamp mode and delayed but vigorous discharges of action potentials in current clamp mode (Figure 8e, left, n = 12 neurons). With higher frequency light pulses, cOpn5 drives more spikes with shorter latencies (~5 s to ~3 s) after the first light pulse, but inward currents are not significantly affected (Figure 9a). In another neuronal subpopulation, brief light pulses rapidly trigger strong inward currents (100-1000 pA) and drive bursting firing of action potentials (Figure 8e, right, n = 6 neurons). Neurons are stimulated repeatedly at 10 Hz, 10 ms / pulse and show a non-decreasing pattern of firing rate in repeated trials of light stimulation (Figure 9b). Of note, unlike action potentials generated by ChR2 optogenetics, action potentials evoked by cOpn5 light stimulation are not time-locked to the light pulse. Finally, we evaluate the application of cOpn5-mediated optogenetics in regulating animal behavior. The lateral hypothalamus (LH) is a brain center known to function in reward processing and feeding behavior. We express cOpn5 in LH GABAergic neurons of VGAT-Cre mice and implant optic fibers to deliver light pulses to the LH of freely behaving mice (Figure 8g). Consistent with previous findings that activation of LHGABA neurons drives feeding behavior,56 photostimulation (20 Hz, 5 ms / pulse, 473 nm, 0.75 mW, output from the fiber tip) elicits a significant increase in food intake in cOpn5-expressing mice but not in control mice expressing EGFP (Figure 8h). Using a food-foraging behavior task, we also tested the effect of cOpn5-mediated optogenetic activation of GABA neurons in the zona incerta (ZI) (Figure 8i), where the zona incerta is a region known to drive compulsive eating.Compared with EGFP-expressing mice, cOpn5-expressing mice show a significant increase in the feeding time of high-fat food pellets after repeated light stimulation (Figure 8j). To characterize the response profile, we perform electrophysiological recordings from cOpn5-expressing neurons in the LH and ZI. Whole-brain sections confirm the injection site and placement of the optical fiber (Figures 10a-10c). Notably, mice maintain the behavior (feeding or high-fat food feeding) when the light is on and immediately stop such behavior when the light is off. Thus, cOpn5 efficiently regulates the behavioral state of animals in a rapid, precise, and reversible manner.

[0063] Here, the present invention relates to q We demonstrate the use of Opn5 in the present invention as a highly effective optogenetic tool for signal transduction and / or cell activation. Previous studies have shown that mammalian Opn5 mediates UV-sensitive G i In mammalian cells that express Opn5 (e.g., expressing cOpn5 or expressing tOpn5), which has been characterized as a conjugated opsin, visible blue light induces rapid Ca 2+ We present the surprising discovery that Opn5 (especially cOpn5) can induce light-induced ATP release in mouse astrocytes in vivo, increasing neuronal activity. The present invention shows that Opn5, particularly cOpn5, allows for rapid, potent and reversible optical activation of neurons, and is applied to selectively regulate animal behavior. Importantly, Opn5 (e.g., cOpn5) in the present invention is a potent and easy-to-use single component system that does not require exogenous chromophores. The present invention shows that Opn5-based optogenetics, e.g., cOpn5-based optogenetics, can enhance G-cell activation in non-excitable and excitable cells. q We envision this being a technique that can be used to study important physiological and behavioral functions regulated by coupled signal transduction and / or activated cells.

[0064] Table 6 shows the enabling properties of cOpn5 by directly comparing response amplitude, light sensitivity, temporal resolution and the need for additional chromophores between cOpn5 and other optogenetic tools. In cOpn5-expressing cells, an intensity of 16 μW / mm 2 Only a 10 ms blue light pulse induced Ca 2+ In contrast, prior to the present invention, opto-a1AR or mammalian Opn4(G q The activation of the two proposed optogenetic tools for signal transduction required approximately three times the light intensity (7–40 mW / mm 2 ) and requires long exposure times (20–60 s), and is sensitive to weak Ca 2+ It is clear that opto-a1AR or mammalian Opn4 only produces a signal (0.25-0.5ΔF / F). Therefore, opto-a1AR or mammalian Opn4 does not produce endogenous G q It is not possible to mimic the rapid activation profile of endogenous G-coupled receptors, where q Coupled receptors typically exhibit strong G responses within subseconds of application of the corresponding ligand. q The striking physiological and behavioral effects shown in vivo in response to cOpn5-mediated optical activation of astrocytes and neurons support the competence of cOpn5 optogenetics. In contrast, a recent systematic characterization showed that opto-a1AR- and Opn4-mediated optogenetic stimulation induces Ca signaling. 2+ The amplitude of the signal did not increase, even after prolonged irradiation. 2+ Our results show that Opn5, specifically cOpn5 or tOpn5, only slightly modulates the frequency of transients and synaptic events in a large number of cells and tissues. By overcoming the limitations in light sensitivity, time resolution and response amplitude associated with opto-a1AR and Opn4-mediated optogenetics, the Opn5 of the present invention (especially cOpn5 or tOpn5) is a novel optogenetic inhibitor that can modulate G signaling in a large number of cells and tissues. q It will have broad applicability in studying the mechanisms and functions of signal transduction and / or cell activation.

[0065] Opn5 (especially cOpn5 or tOpn5)-based optogenetics of the present invention also has the advantages of safety and convenience. Although Opn5 in many species has been reported to be UV-responsive (Kojima et al., 2011), cOpn5 is optimally activated by 470 nm blue light, and the penetration of blue light is superior to that of UV, avoiding UV-related cytotoxicity. The ultra-sensitivity to light also minimizes potential heating artifacts. Two-photon activation can be achieved using long wavelength (≧920 nm) light, indicating that it is suitable for deeper tissue activation using pulsed lasers. cOpn5 or tOpn5 is potently and reproducibly activated by light without the need for exogenous retinal, which is likely because cOpn5 or tOpn5 is a bistable opsin that is covalently bound to endogenous retinal, and therefore resistant to photobleaching (Koyanagi and Terakita, 2014; Tsukamoto and Terakita, 2010). In contrast, Opn4 mammalian experiments require additional retinal, have a long response time, and are less photosensitive. The Opn5 of the present invention (especially cOpn5 or tOpn5) is particularly useful for in vivo studies as a single-component system, since it avoids the burden of delivering compounds to tissues during experiments.

[0066] Compared to chemical genetics and uncaging tools, the Opn5 optogenetics of the present invention (especially cOpn5 or tOpn5 optogenetics) further offers several important advantages: It is much more precise in time and offers single-cell or subcellular spatial resolution. CNO / hM3Dq-mediated chemical genetics has been used to study the physiological and behavioral functions of non-excitable cells (e.g., astrocytes in the brain) (Agulhon et al., 2013; Shen et al., 2021), but in vivo use often requires several minutes for CNO to reach the target cells and tissues. The diffusive nature of the compound allows for G-phase analysis at cellular and subcellular resolution. qThis suggests that chemogenetic stimulation of signal transduction is nearly impossible. The Opn5 of the present invention (especially cOpn5 or tOpn5) is also different from caged compound-based "uncaging" tools (e.g., caged calcium and caged IP3), which require preloading of compounds and are G q Ca associated with signal transduction and / or cell activation 2+ This is because they only partially mimic the relevant pathways. For example, there are other "uncaging" tools such as caged glutamate and caged ATP (Ellis-Davies, 2007, Lezmy et al., 2021) that target endogenous GPCRs. However, these caged compounds require introduction into the extracellular medium or into the cytoplasm within the cells, limiting their application to behavioral animals (Adams and Tsien, 1993b). The advantages of the Opn5 (especially cOpn5 or tOpn5) of the present invention over the "uncaging" tools have been clearly demonstrated by experiments, and the Opn5 (especially cOps5 or tOpn5) of the present invention is similar to existing ChR2-based tools and can be used to regulate animal behaviors with similar ease.

[0067] The optogenetics of Opn5 (particularly cOps5 or tOpn5) of the present invention can be used to detect intracellular G q It is particularly suitable for signal transduction and / or precise activation of cells, followed by the release of accumulated intracellular Ca 2+ The Opn5 (especially cOpn5 or tOpn5) of the present invention is different from current channel-based optogenetic tools, such as ChR2 or its variants, which transport cations across the cell membrane. By controlling the cell membrane potential and thus the discharge of action potentials, ChR2 and its variants have made significant contributions to the dissection of neural circuits, but their success has been more limited in the study of non-excitable cells that lack active ion channels that generate action potentials (Gourine et al., 2010). In addition to being applied to non-excitable cells, the optogenetics of Opn5 (especially cOpn5 or tOpn5) of the present invention can be used to study G in neurons. qThey can also stimulate signal transduction and / or neuronal activation to control animal behavior in a circuit-dependent manner. q Coupled GPCRs may recruit G proteins indiscriminately and generate variable downstream signaling in a receptor- and cell-specific manner. Indeed, it is observed that the same light illumination parameters generate different activation patterns in different neurons. The Opn5 (especially cOpn5 or tOpn5)-mediated optogenetic activation of the present invention does not generate strictly time-locked action potential firing in neurons as ChR2 does. This may be useful because it avoids artificially synchronized neuronal activation. However, when precise time control of action potential firing is required, we recommend the use of ion channel-based optogenetic tools.

[0068] In addition to technological advances, our findings may have several functional effects on astrocyte signaling and / or activation in vivo. ATP is thought to be an important gliotransmitter, but previous studies have revealed multiple release mechanisms, and these release mechanisms may vary depending on the processing method, extracellular Ca2+, and other factors. 2+ The presence of ATP depends on the exact morphology of the cell and tissue preparation samples (Figueiredo et al., 2014; Hamilton and Attwell, 2010). Moreover, the presence of ATP release is usually monitored indirectly. It is unclear whether activation of astrocytes causes ATP release and, if so, how such release manifests in vivo. Here, we investigate the mechanism by which ATP release in astrocytes is expressed by the G qWe first demonstrated that stimulation of signaling pathways triggers massive ATP release in the form of ATP flashes. Our optogenetics of Opn5 (especially cOpn5 or tOpn5) provides an ideal technique to study the molecular and cellular mechanisms of ATP release. In addition to ATP, activation of astrocytes also triggers the release of other gliotransmitters such as D-serine, glutamate and GABA. ATP is also converted to other metabolites such as adenosine. Glial transmitters and their metabolites may exert complex regulatory effects on neuronal excitability and synaptic strength. For example, ATP can activate neurons through various P2X and P2Y receptors, whereas adenosine potently inhibits neurons through A1 receptors (Lezmy et al., 2021; Zhang et al., 2003). It is unclear how these different effects are integrated to regulate neuronal activity in vivo. Here, we show that optogenetic activation of cOpn5-expressing astrocytes significantly stimulates neurons in the mouse S1 cortex. Thus, the optogenetics of the Opn5 (particularly cOpn5 or tOpn5) of the present invention lays the foundation for dissecting the molecular, cellular and circuit mechanisms of the complex interactions between astrocytes and neurons. In vivo experiments have demonstrated that the Opn5 (particularly cOpn5 or tOpn5) of the present invention can be used as an optogenetic probe and imaging sensor (e.g., genetically encoded Ca 2+ The Opn5 of the present invention (particularly cOpn5 or tOpn5) is compatible with these sensors and GPCR-based neurotransmitter sensors. q This could potentially enable all-optical approaches to transiently activate signaling and / or cells and simultaneously monitor the associated effects.

[0069] In summary, the present invention provides a method for the preparation of Opn5 of the present invention (particularly cOpn5 or tOpn5) that qThe present invention demonstrates that Opn5 acts as a blue light-sensitive opsin for rapid, reversible and precise activation of signal transduction and / or cells. The present invention establishes Opn5 (particularly cOpn5 or tOpn5) of the present invention as a powerful and easy-to-use optogenetic tool for activating non-excitable cells and neurons. q Given the importance of coupled GPCRs, cOpn5 is a key regulator of GPCR signaling in all major cell types and tissues. q This is expected to have a wide range of applications in elucidating the detailed mechanisms and functions of signal transduction.

[0070] The descriptions of specific embodiments and examples are provided by way of illustration and not limitation, as those skilled in the art will readily recognize that a variety of non-critical parameters can be changed or modified to produce substantially similar results.

[0071] Working Example material and method: [Table 1]

[0072] [Table 2]

[0073] [Table 3]

[0074] [Table 4]

[0075] [Table 5]

[0076] [Table 6-1] [Table 6-2]

[0077] Example 1.G q cOpn5 mediates optogenetic activation of signaling Heterologous expression of Opn5 orthologs from chicken, sea turtle, human and mouse (which share 80–90% protein sequence identity with each other) suppressed blue light-induced G signaling in HEK293T cells. q The ability of the cells to mediate signaling activation was tested using blue light stimulation and red intracellular calcium indicator Calbryte (Figure 1a and Table 7). TM Relative Ca using 630AM dye 2+ The Opn5 orthologues from chicken (cOpn5) and sea turtle (tOpn5) were used to monitor the Ca response (Figure 1b). 2+ cOpn5 mediates an immediate and strong light-induced increase in signal (approximately 3ΔF / F), whereas no light effect is observed in cells expressing human or mouse Opn5 orthologues (Fig. 1d and Fig. 2a,b). As exemplified by the chicken orthologue, cOpn5 colocalizes with the EGFP-CAAX membrane marker, indicating that it is efficiently transported to the plasma membrane (Fig. 1c). No exogenous retinal was added to the medium, indicating that endogenous retinal is sufficient to drive cOpn5. Ca 2+ The signal is extracellular Ca 2+ Ca from intracellular stores is resistant to removal of 2+ The release of YM-254890 (highly selective G q Protein Inhibitors 33 ) reduced light-induced Ca in both cOpn5-expressing cells. 2+The light-induced increase in the levels of inositol phosphate (IP1), a rapid degradation product of IP3, was detected in cOpn5 (but not human OPN5)-expressing cells, and the magnitude of the increase was reduced by treatment with YM-254890 (Fig. 1f and Fig. 2d). In cOpn5-expressing HEK293T cells, blue light also inhibited the activation of MARCKS protein (a known target point of PKC) in a PKC activity-dependent manner. 34 ) phosphorylation (Fig. 1g and Fig. 2e). In contrast, blue light irradiation efficiently reduces cAMP levels in human and mouse Opn5-expressing cells in the presence of retinal, but has no such effect in cOpn5-expressing cells without retinal (Fig. 2f). Taken together, these data suggest that blue light irradiation reduces G q Supporting the coupling of cOpn5 to signal transduction pathways.

[0078] [Table 7]

[0079] Figure 1. cOpn5 inhibits light-induced G signaling in HEK293T cells. q We show that it mediates potent activation of signal transduction. a. Schematic of putative intracellular signaling in response to light-induced cOpn5 activation. PLC: phospholipase C; PIP2: phosphatidylinositol-4,5-bisphosphate; IP3: inositol-1,4,5-triphosphate; IP1: inositol monophosphate; DAG: diacylglycerol; PKC: protein kinase C; YM-254890: selective G q Protein inhibitors.

[0080] b. Three species of Opn5-expressing HEK293T cells (Gallus gallus, Homo sapiens, and Mus musculus) were stimulated with blue light (10 s, 100 μW / mm 2 , 488 nm) before and after Ca 2+Pseudocolor image of the signal. Scale bar, 10 μm.

[0081] c. Cy3 counterstained V5-cOpn5 fusion protein (red) colocalizes with membrane tagged EGFP-CAAX (green) in HEK293T cells. DAPI counterstain (blue) supports the cell nuclei. Scale bar, 10 μm.

[0082] dc shows light-induced Ca 2+ The signal change over time is shown.

[0083] eG q The protein inhibitor YM-254890 (10 nM) inhibited cOpn5-mediated light-induced Ca 2+ Reversibly blocks the signal.

[0084] f. In cOpn5-expressing HEK293T cells, YM was stimulated with continuous light (100 μW / mm for 3 min). 2 , 470 nm) induced IP1 accumulation (left). ***P<0.0001, *P=0.0128, Tukey's multiple comparison test.

[0085] g. Phosphorylation of MARCKS in cOpn5-expressing HEK293T cells in the control group (no light stimulation), light stimulation group, and light + staurosporine (ST, PKC inhibitor) group. The amount of p-MARCKS in the same fraction is normalized to the amount of α-tubulin. **P=0.0096, ***P=0.0004, Tukey's multiple comparison test.

[0086] Figure 2 shows that cOpn5 is G q Signal transduction is coupled to G i This indicates that it is not coupled to signal transduction. a. Opn5-expressing HEK293T cells from a marine turtle species (Chelonia mydas) were stimulated with blue light (10 s, 100 μW / mm 2 , 488nm) before and after Ca 2+ Pseudocolor images of the signal. Scale bar, 10 μm (left); evoked Ca in responding cells.2+ Signal change over time (right).

[0087] bG q The protein inhibitor YM-254890 (10 nM) inhibited cOpn5 and sea turtle Opn5-mediated light-induced Ca 2+ Group data for reversibly blocked signal. ****P<0.0001, one-way ANOVA. Error bars indicate SEM.

[0088] c. Extracellular Ca 2+ In the absence of 2 , 470 nm) 2+ Signal change over time.

[0089] d. IP1 accumulation in human Opn5-expressing HEK293T cells with or without light stimulation with oil (right). ns, not significant difference, unpaired t test.

[0090] e. Representative results of phosphorylation of MARCKS in cOpn5-expressing HEK293T cells in the control group (no light stimulation), the light stimulation group, and the light + staurosporine group. The amount of p-MARCKS in the same fraction is normalized to the amount of α-tubulin.

[0091] f. Light has no effect on cAMP levels in cOpn5-expressing HEK293T cells without the addition of retinal in the medium (10 μM forskolin preincubation) (left). Right panel shows the effect of light stimulation on cAMP concentrations in four different species of Opn5-expressing HEK293T cells after 10 μM retinal preincubation.

[0092] Error bars in d and f indicate SEM.

[0093] Example 2. Sensitive and accurate cOpn5-mediated optogenetics We characterized the light-activation properties of cOpn5 heterologously expressed in HEK293T cells. Opn5 has previously been considered an ultraviolet (UV)-sensitive photoreceptor, but was activated only at a fixed light intensity (100 μW / mm 2 ) plotting a series of wavelengths in the range 365-630 nm, blue light at 470 nm is the strongest Ca 2+ Whereas UVA light (365 and 395 nm) was less efficient and longer wavelength visible light (561 nm or longer) had no effect at all (Figure 3a). We tested the effect of different light durations on cOpn5-expressing HEK293T cells. Short light pulses (1, 5, 10, 20, 50 ms, 16 μW / mm 2 , 470 nm) stimulates Ca when the light duration exceeds 10 ms. 2+ The response reaches saturation mode (Figure 3b). 2 , 470 nm), even with prolonged light duration, 2+ The signal amplitude is not further increased (Figure 4a). Irradiation with 470 nm light at different intensities results in a signal amplitude of approximately 4.8 μW / mm 2 and 16 μW / mm 2 Blue light at 1000 nm produces approximately half and maximal responses, respectively (Figure 3c and Figure 4b). Thus, the light sensitivity of cOpn5 is consistent with that of the light-sensitive G q These values ​​are 3-4 orders of magnitude higher than reported values ​​for coupled GPCRs and even 2-3 orders of magnitude higher than those for channelrhodopsin-2 (ChR2), a commonly used optogenetic tool (Lin, 2011; Zhang et al., 2006) (Table 8). Taken together, these results demonstrate that cOpn5 can function as a single-component optogenetic tool without the addition of retinal and that low light intensities (16 μW / mm) are required for full activity. 2 ) and short duration (10 ms), indicating that cOpn5 is hypersensitive to blue light.

[0094] [Table 8-1] [Table 8-2]

[0095] The performance of cOpn5 was compared with that of opto-a1AR, where opto-a1AR is a rhodopsin-G q This is a chimeric GPCR engineered by mixing a GPCR with a GPCR-coupled adrenergic receptor. 14 We performed Ca ion channel analysis in opto-a1AR-expressing HEK293T cells according to the protocol described in the literature. 2+ A very long and intense exposure (60 s, 7 mW / mm) was required to induce a slow and small (~0.5 ΔF / F) increase in signal. 2 ) was required for the cells to be exposed to light, whereas 15 seconds of illumination was found to be ineffective (Fig. 4c, d). The performance of cOpn5 was compared to that of opn4, where opn4 is the native opsin and G q It has been reported to be a tool used to activate signal transduction. Prolonged exposure to intense radiation (25 s, 40 mW / mm 2 ) and additional retinal induces a slow (~1ΔF / F) Ca in opn4-expressing HEK293T cells. 2+ It is found that cOpn5 induces an increase in the signal (Figure 4e, Figure 4f). Thus, compared to existing opsin-based tools (opto-a1AR and opn4), cOpn5 is much more light sensitive (approximately three orders of magnitude more sensitive), requires much shorter exposure times (10 ms versus 60 s), and generates a stronger response.

[0096] Furthermore, we compared the performance of cOpn5 with that of a general G q Compare the performance of the conjugated chemical genetics tool hM3Dq, the latter of which is activated by the addition of the exogenous small molecule ligand clozapine-N-oxide (CNO) 37-39 Light-induced activation of cOpn5-expressing HEK293T cells and CNO-induced activation of hM3Dq-expressing HEK293T cells were observed in similar Ca 2+with the peak value response amplitude of the signal. At the same time, compared with hM3Dq-expressing HEK293T cells, cOpn5-expressing HEK293T cells exhibit faster and more temporally precise responses and faster recovery times (Figure 4g-Figure 4i). These results indicate that cOpn5-mediated optogenetics is more controllable than hM3Dq in terms of temporal precision.

[0097] cOpn5 optogenetics allows precise spatial control of cellular activity. Restricting brief light stimulation (63 ms) to subcellular regions of individual cOpn5-expressing HEK293T cells results in immediate activation of individual cells. Interestingly, in highly confluent regions, Ca 2+ The signal propagates to surrounding cells, suggesting the presence of intercellular communication between HEK293T cells by a yet unidentified mechanism (Figure 3d, e). The findings are also extended to primary cell cultures. In primary astrocyte cultures prepared from neonatal mouse brains, cOpn5 is expressed using an AAV vector for bicistronic expression of cOpn5 and EGFP marker proteins (Figure 5a). Calbryte 630AM dye was used to measure Ca 2+ When blue light was irradiated onto cOpn5-expressing astrocytes, a strong Ca 2+ We found that the Ca transients were positive (~8ΔF / F) (Figure 5b, c). When light stimulation (63 ms) was precisely restricted to the subcellular regions of individual cOpn5-expressing astrocytes, the Ca transients were positive (~8ΔF / F) (Figure 5b, c). 2+ We observed that the signal was propagated within individual cells (Fig. 3f). Similar to the study in HEK293T cells, Ca signals were transmitted from stimulated astrocytes to more distal unstimulated astrocytes. 2+ A gentle wave-like propagation of the signal is observed (Fig. 3g, h). Thus, these experiments confirm that precise spatial control is possible with cOpn5 optogenetics and suggest that it may be useful to study the dynamics of the astrocytic networks originally discovered using neurochemical and mechanical stimulation. 40、41 .

[0098] Figure 3 shows that cOpn5 mediates G q We demonstrate that the sensitivity of β-glucosidases mediates optical control of signal transduction. a. Ca in HEK293T cells expressing selected wavelengths (365, 395, 470, 515, 561, 590 and 630 nm, left panel) and cOpn5 in response to light stimulation at different wavelengths. 2+ Signal amplitude (2s, 100μW / mm 2 Schematic diagram of the 3D-cell hybridization reaction (right panel). Error bars indicate SEM.

[0099] b. Different light stimulation durations (1, 5, 10, 20 or 50 ms, 16 μW / mm 2 , 470 nm). Error bars indicate SEM.

[0100] c. cOpn5-mediated Ca2+ expression under different light intensities 2+ Signal change over time (0, 4.8, 8, 16 or 32 μW / mm 2 , 10ms, 470nm, 10ms 16μW / mm 2 For stimulation, 10% peak value activity = 1.36 ± 0.55 s, 90% peak value activity = 2.37 ± 0.87 s, decay time τ = 18.66 ± 4.98 s, mean ± SEM, n = 10 cells).

[0101] d. Light-induced (63 ms, 17 μW, arrows indicate the stimulation area) Ca in cOpn5-expressing HEK293T cells. 2+ Image of signal propagation. Scale bar, 10 μm.

[0102] Time course of Ca 2+ Pseudocolor image showing signal propagation (frame N / (N-1)>1). The frame interval is 500 ms and each frame is counted once.

[0103] f. Light-induced Ca in individual cOpn5-expressing primary astrocytes stimulated in the subcellular region 2+ Image of signal propagation (stimulus size is 4 × 4 μm 2(The frame interval was 300 ms.) Scale bar, 10 μm.

[0104] g. Light-induced Ca in cOpn5-expressing primary astrocytes 2+ Image of signal propagation. Scale bar, 10 μm.

[0105] Ca concentration in hg 2+ Pseudocolor image showing signal propagation (frame N / (N-1)>1). The frame interval is 500 ms and each frame is counted once.

[0106] FIG. 4 shows that cOpn5 mediates a more rapid and sensitive response to light than opto-a1AR, hM3Dq or opn4. a. Light pulse (16 μW / mm 2 , 470 nm, 1, 5, 10, 20 or 50 ms) 2+ Signal change over time.

[0107] b. Different light intensities (0, 4.8, 8, 16 or 32 μW / mm) at 470 nm for 10 ms. 2 ) response amplitude under

[0108] c. Baseline and peak Ca values ​​in opto-a1AR-expressing HEK293T cells 2+ Pseudocolor image of signal (ΔF / F0). Culture buffer contains 10 μM all-trans retinal. Scale bar, 30 μm.

[0109] d. Ca in opto-a1AR-expressing HEK293T cells 2+ Effects of 60 s of light stimulation on Ca (n=15 cells, upper panel). 15 s of light stimulation increased Ca 2+ It does not affect the signal (see below).

[0110] e. Baseline and peak Ca values ​​in human OPN4-expressing HEK293T cells 2+Pseudocolor image of signal (ΔF / F0). Culture buffer contains 10 μM all-trans retinal. Scale bar, 30 μm.

[0111] f. In opn4-expressing HEK293T cells, Ca 2+ Effect of 25 s of light stimulation under 10 uM ATR on Ca in the absence of ATR (n=12 cells, red line). 2+ No effect on the signal (black).

[0112] g. Ca in cOpn5-expressing HEK293T cells 2+ Effects of light stimulation on the signal. Top panel shows pseudocolor images of baseline and peak value responses. Bottom panel shows Ca responses induced by cOpn5-mediated optogenetic stimulation in cOpn5-expressing HEK293T cells over five consecutive trials. 2+ Signal heatmaps are shown. Scale bar, 20 μm.

[0113] h. Ca in hM3Dq-expressing HEK293T cells 2+ Effects of chemogenetic stimulation on signaling.

[0114] i. Ca induced by cOpn5-mediated optogenetic stimulation (10 s) and hM3Dq-mediated chemogenetic stimulation using CNO puffs (100 nM, 10 s), respectively. 2+ Signal change over time.

[0115] FIG. 5 shows that cOpn5 efficiently mediates astrocyte activation. AAV-cOpn5-T2A-EGFP (green) is used to express cOpn5 in cultured primary astrocytes. Astrocyte identity is confirmed by GFAP immunostaining (red). Scale bar, 20 μm.

[0116] b. Baseline and peak Ca values ​​in cOpn5-expressing astrocytes after light stimulation 2+ Pseudocolor image of the signal. Scale bar, 20 μm.

[0117] c.Ca 2+ Diagram of the signal and Ca across trials 2+ Heatmap of signals (n=25 cells).

[0118] Example 3. Optogenetic activation of cOpn5 in astrocytes induces massive ATP release and neuronal activation in vivo Test the in vivo performance of cOpn5-mediated optogenetics. Astrocytes represent an important population of non-excitable cells in the central nervous system, and to date, optogenetic tools have met with limited success in this population. 42 ATP is known to be a communication messenger between astrocytes, but the intracellular Ca response to ATP release is unclear. 2+ The real-time effects of ATP have yet to be visualized. ATP We use ATPases to monitor changes in extracellular ATP levels. Specifically, we monitored the expression of cOpn5 and GRAB in mouse S1 sensory cortex after injection of AAV vectors containing the GfaABC1D promoter (commonly used to drive gene expression in astrocytes). ATP The sensor is expressed (Figure 6a).

[0119] Two-photon imaging of GRABATP signals from a head-fixed awake, normally behaving mouse (Figure 6a). We initially anticipate that a blue light pulse would be necessary to stimulate ATP signals in addition to the 920 nm light of the pulsed laser used for two-photon imaging. Surprisingly, the 920 nm light delivered for imaging itself does not stimulate cOpn5 and GRABATP signals. ATPcOps5 expression elicits massive ATP flashes in mice expressing cOps5 but not in mice expressing the ATP sensor but lacking cOps5 expression. The diameter of individual ATP flashes is typically in the range of 20–100 μm and lasts for approximately 1 min. After an initial quiescent period of approximately 1 min, the flash frequency gradually increases, reaching a peak value within approximately 5 min and expanding beyond the imaging area (640 × 640 μm). 2 ) reaches a level of about 50 flashes / min (Figures 6b, 6c and 7a). Furthermore, high frequency ATP flashes also appear on repeated testing (Figure 7b). ATP In mice expressing only Opn5, sporadic ATP events (approximately 0.3 flashes / min within the imaging field) were observed, whereas 8 h after proinflammatory treatment with intraperitoneal injection of lipopolysaccharide (LPS), ATP flash events increased almost 6-fold above basal conditions (approximately 2 flashes / min), but showed a fairly stable frequency, confirming that inflammation induces ATP release in the brain. Considering that the ATP flash frequency observed in cOpn5-expressing mice was approximately 25-fold higher (Figure 6d, Figure 7c) than the flash frequency after proinflammatory treatment in mice not expressing Opn5, we demonstrate that cOpn5-mediated photoactivation of astrocytes induces continuous and massive ATP release in vivo.

[0120] Astrocytes release ATP, and other gliotransmitters, acting on neuronal receptors to regulate neuronal activity. Using cOpn5-mediated astrocyte activation, we investigated the effects of cOpn5 on neuronal Ca in head-fixed, awake, normally behaving mice. 2+Two-photon imaging of the signal (Figure 6e). cOpn5-expressing cells (n=406) colocalize with GFAP staining (n=397) but not with GCaMP7b-expressing neurons (Figure 6f). Raw tracking example and cohort data show that cOpn5-mediated astrocyte activation significantly increases neuronal activity from 15-20 min compared to 0-5 min (Figure 6g, Figure 6h and Figure 7d). cOpn5 is strictly expressed in astrocytes, which is confirmed by the colocalization of cOpn5-expressing cells and GFAP staining signals (different from GCaMP7b signals in neurons). We have demonstrated that cOpn5-mediated astrocyte photoactivation increases peripheral neuronal activity in vivo. Furthermore, our data show that long-wavelength (920 nm) light from pulsed lasers used for two-photon imaging can activate cOpn5, suggesting that cOpn5 has the potential for two-photon optogenetics.

[0121] FIG. 6 shows that cOpn5-mediated astrocyte activation induces a massive ATP flush and neuronal activation in vivo. a. Schematic of the experimental setup for in vivo two-photon imaging (920 nm) of ATP release after cOpn5-mediated astrocyte activation. Images show expression of cOpn5 (red) in astrocytes and GRAB expression in astrocytes in mouse S1 cortex. ATP Expression of the sensor (green) is shown. Scale bar, 100 μm.

[0122] b. Time course (0–10 min) of the number of astrocyte ATP flash events in control mice (no cOpn5 expression), LPS-treated mice (no cOpn5 expression), and cOpn5-expressing mice (right side).

[0123] c. Total ATP flush events in control mice (no cOpn5 expression), LPS-treated mice (no cOpn5 expression) and cOpn5-expressing mice. The left column shows raw GRAB events at basal levels (before light exposure). ATP The middle column shows the images taken at 5 min.ATP The signals are shown, and the right column shows pseudocolor-coded ATP flash events accumulated from 0 to 20 min.

[0124] d Raster plot of astrocytic ATP flash events over time, corresponding to the data shown in c.

[0125] e. Schematic of the experimental setup to perform in vivo two-photon imaging (920 nm) for neuronal calcium imaging after cOpn5-mediated astrocyte activation. Images show expression of cOpn5 (red) in astrocytes and expression of GCaMP7b (green) in astrocytes within mouse S1 cortex. Scale bar, 100 μm.

[0126] f. cOpn5-expressing cells (red) colocalize with GFAP cells (purple) counterstained with 647 nm dye, and GCaMP7b-expressing cells (green) are neurons. 406 red cells and 397 purple cells, Scale bar, 100 μm.

[0127] g. Time traces of 10 GCaMP7b-expressing neurons within 0–5 min and 15–20 min coupled with cOpn5-mediated astrocyte activation.

[0128] h. Analysis of calcium events in GCaMP7b-expressing neurons within 0–5 and 15–20 min coupled to cOpn5-mediated astrocyte activation. N=193 neurons, ****P<0.0001, unpaired t-test.

[0129] FIG. 7 shows that cOpn5 mediates sustained and robust ATP release in astrocytes and activation of peripheral neurons. a. Example of an astrocytic ATP flash event detected in cOpn5-expressing mice, showing individual flashes in different colors.

[0130] b ATP flush events (0–20 min) in cOpn5-expressing mice upon repeated testing 1 h later.

[0131] c. Quantification of the number of ATP flush events in control, LPS and cOpn5 groups. Control-LPS comparison, **P=0.0066; LPS-cOpn5 comparison, **P=0.0031; Control-cOpn5 comparison, ***P=0.0002, unpaired t-test.

[0132] d. Analysis of decoded spike firing rates of GCaMP7b-expressing neurons within 0–5 min and 15–20 min coupled to cOpn5-mediated astrocyte activation. N = 193 neurons, ***P < 0.0001, unpaired t test.

[0133] Example 4. cOpn5 optogenetics to activate neurons and regulate animal behavior We will investigate the application of cOpn5-mediated optogenetics in neurons. First, we will show that cOpn5 regulates light-induced Ca 2+ We used AAV and the pan-neuronal SYN promoter to express cOpn5 and genetically encoded Ca signals in mouse cortical neurons. 2+ In the brain slice samples, a blue light pulse (10 s, 100 μW / mm 2 , 473 nm) in neurons. 2+ cOpn5 robustly induced light-induced transients (Figure 8b, c). Thus, cOpn5 can also mediate light-induced activation in neurons.

[0134] We study the effects of light-induced cOpn5 activation on the electrophysiological properties of neurons in slice samples from the motor cortex, hippocampus and dorsal striatum (Fig. 8d). Two types of activation patterns are observed. In most recorded neurons, blue light pulses induce small depolarizing currents (~20 pA) in voltage clamp mode and delayed but vigorous discharges of action potentials in current clamp mode (Fig. 8e, left, n = 12 neurons). Under higher frequency light pulses, cOpn5 drives more spikes and has a shorter latency period (~5 s to ~3 s) after the first light pulse, and inward currents are not significantly affected (Fig. 9a). In another subpopulation of neurons, a brief light pulse rapidly triggers a strong inward current (100-1000 pA) and drives burst firing of action potentials (Fig. 8e, right, n = 6 neurons). Neurons are stimulated repeatedly at 10 Hz, 10 ms / pulse, and show a non-decreasing pattern of firing rate upon repeated trials of light stimulation (Figure ​(Figure9b). ​Notably, unlike action potentials generated by ChR2 optogenetics,53 action potentials evoked by cOpn5 light stimulation are not time-locked to the light pulse.

[0135] Finally, we will evaluate the utility of cOpn5-mediated optogenetics in modulating animal behavior. The lateral hypothalamus (LH) is a brain center known to function in reward processing and feeding behavior. 54,55 We expressed cOpn5 in LH GABAergic neurons in VGAT-Cre mice, implanted optical fibers, and delivered light pulses to the LH of freely behaving mice (Figure 8g). Activation of LH GABA neurons was shown to mediate feeding behavior. 56Consistent with previous findings that cOpn5 drives compulsive eating, light stimulation (20 Hz, 5 ms / pulse, 473 nm, 0.75 mW, output from the fiber tip) evoked a significant increase in food intake in cOpn5-expressing mice but not in EGFP-expressing control mice (Figure 8h). Using a food-foraging task, we also tested the effect of cOpn5-mediated optogenetic activation of GABA neurons in the zona incerta (ZI) (Figure 8i), an area known to drive compulsive eating. 57 Compared with EGFP-expressing mice, cOpn5-expressing mice show a marked increase in the time spent foraging for high-fat food pellets after repeated light stimulation (Figure 8j). To characterize the response profile, we perform electrophysiological recordings from cOpn5-expressing neurons in the LH and ZI. Whole-brain sections confirm the injection site and placement of the optical fiber (Figure 10a-c). Of note, mice maintain the behavior (feeding or high-fat food foraging) when the light is on and immediately stop such behavior when the light is off. Thus, cOpn5 can efficiently regulate the behavioral state of animals in a rapid, precise, and reversible manner.

[0136] FIG. 8 shows that cOpn5-mediated optogenetics alters mouse behavior in a neural circuit-dependent manner. A. Optogenetic stimulation and Ca 2+ Schematic showing the experimental set-up for imaging.

[0137] b. Light stimulation (10s, 100μW / mm 2 , 473 nm) around Ca 2+ Pseudocolor images showing signal. Scale bar, 10 μm.

[0138] Ca in six neurons in cb 2+ A diagram showing a signal trace.

[0139] d. Schematic showing optogenetic stimulation and whole-cell patch clamp recording of cOpn5-expressing neurons in the cortex, striatum and hippocampus.

[0140] e. Representative diagram of two types of neurons, one showing strong, delayed action potential firing and a small sustained inward current in response to a light pulse (1 Hz, 5 s, 10 ms / pulse), the other showing a rapid membrane potential depolarization and a large inward current.

[0141] f. After applying a 473 nm light stimulation pulse signal (1 Hz, 5 s), the firing rate of neurons increases (***P = 0.0005, n = 18, unpaired t test).

[0142] g. Schematic of the experimental setup used for optogenetics and food intake measurements. cOpn5-EGFP is expressed in GABAergic neurons within the lateral hypothalamus (LH) of VGAT-Cre mice. EGFP is expressed as a control.

[0143] h. Summary of light-induced (20 Hz, 5 ms / pulse, 473 nm, 0.75 mW, output from fiber tip) activation of cOpn5-mediated feeding behavior. ***P=0.0003, ns, not significant, n=6 mice, unpaired t-test. Error bars represent SEM.

[0144] i. Schematic of the experimental setup used for food foraging behavior. High-fat food pellets are used. cOpn5-EGFP is expressed in GABAergic neurons within the zona incerta (ZI) of mice. EGFP is expressed as a control.

[0145] j. Summary of cOpn5-mediated foraging behavior. The percentage of foraging time from receiving the light stimulus until the mouse found the hidden food was calculated. ****P<0.0001, n=6 mice, unpaired t-test. Error bars indicate SEM.

[0146] FIG. 9 shows that cOpn5-mediated optogenetics robustly activates neurons. a. One representative neuron responding to 1, 10 and 20 Hz light pulses (5 s, 10 ms / pulse).

[0147] b. Raw traces showing reliable and repeatable cOpn5-mediated neuronal photoactivation.

[0148] c. Summary of firing rates during repeated light stimulation trials.

[0149] FIG. 10 shows the injection location and arrangement of the optical fiber. a. Image showing EGFP control expression and bicistronic expression of cOpn5 (white dashed line) in the LH. The lesion site and blue dashed line indicate the placement of the optical fiber. Scale bar, 500 μm.

[0150] b. Injection location and optical fiber placement in the ZI. Scale bar, 500 μm.

[0151] c. Electrophysiological recordings of cOpn5-expressing neurons in the LH and ZI characterize cOpn5-mediated optogenetic activation.

[0152] Example 5 Experimental Description: Table 9 below is a partial list of cOpn5 orthologs from vertebrata that were tested in the present invention. The complete genes of all reported opsin 5 orthologs from vertebrata (including rotundia, cartilaginous fish, bony fish, amphibians, reptiles, birds and mammals) are synthesized and expressed in HEK293T cells. To test the sensitivity of opsin 5 orthologs to light, calcium imaging is performed with or without 470 nm blue light stimulation. The time course of light-induced calcium signal is monitored by G q We will clarify the degree of differential activation of signaling pathways and the sensitivity of these orthologs.

[0153] [Table 9-1] [Table 9-2] [Table 9-3]

Table 9-4

Table 9-5

Table 9-6

Table 9-7

Table 9-8

Table 9-9

Table 9-10

Table 9-11

Table 9-12

Table 9-13

Table 9-14

Table 9-15

Table 9-16

Table 9-17

[0154] References 1.Hauser, AS, Attwood, MM, Rask-Andersen, M., Schioth, HB & Gloriam, DE, Trends in GPCR drug discovery: new agents, targets and indications, Nat Rev Drug Discov 16, 829-842, doi:10.1038 / nrd.2017.178 (2017). 2.Wettschureck, N. & Offermanns, S.,Mammalian G proteins and their cell type specific functions,Physiol Rev 85, 1159-1204, doi:10.1152 / physrev.00003.2005 (2005). 3.Exton, JH, Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins, Annu Rev Pharmacol Toxicol 36, 481-509, doi:10.1146 / annurev.pa.36.040196.002405 (1996). 4.Ritter, SL & Hall, RA, Fine-tuning of GPCR activity by receptor-interacting proteins, Nature reviews Molecular cell biology 10, 819-830 (2009). 5. Kadamur, G. & Ross, EM, Mammalian phospholipase C, Annu Rev Physiol 75, 127-154, doi:10.1146 / annurev-physiol-030212-183750 (2013). 6. Gomez, JL et al., Chemogenetics revealed: DREADD occupancy and activation via converted clozapine, Science 357, 503-507, doi:10.1126 / science.aan2475 (2017). 7.Adams, SR & Tsien, RY, Controlling cell chemistry with caged compounds, Annual review of physiology 55, 755-784 (1993). 8.Boyden, E.S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K., Millisecond-timescale, genetically targeted optical control of neural activity, Nat Neurosci 8, 1263-1268, doi:10.1038 / nn1525 (2005). 9. Fenno, L., Yizhar, O. & Deisseroth, K., The Development and Application of Optogenetics, Annual Review of Neuroscience 34, 389-412, doi:10.1146 / annurev-neuro-061010-113817 (2011). 10.Quadrato, G. et al., Cell diversity and network dynamics in photosensitive human brain organoids, Nature 545, 48-53 (2017). 11. Rost, B. R., Schneider-Warme, F., Schmitz, D. & Hegemann, P., Optogenetic tools for subcellular applications in neuroscience, Neuron 96, 572-603 (2017). 12.Tye, KM & Deisseroth, K.,Optogenetic investigation of neural circuits underlying brain disease in animal models,Nature Reviews Neuroscience 13, 251-266 (2012). 13.Zhang, F. et al., The microbial opsin family of optogenetic tools, Cell 147, 1446-1457 (2011). 14. Airan, RD, Thompson, KR, Fenno, LE, Bernstein, H. & Deisseroth, K., Temporally precise in vivo control of intracellular signalling, Nature 458, 1025-1029, doi:10.1038 / nature07926 (2009). 15. Tichy, AM, Gerrard, EJ, Sexton, PM & Janovjak, H. Light-activated chimeric GPCRs: limitations and opportunities, Curr Opin Struct Biol 57, 196-203, doi:10.1016 / j.sbi.2019.05.006 (2019). 16. Koyanagi, M. & Terakita, A. Diversity of animal opsin-based pigments and their optogenetic potential, Biochim Biophys Acta 1837, 710-716, doi:10.1016 / j.bbabio.2013.09.003 (2014). 17.Yau, K.-W. & Hardie, R.C., Phototransduction motifs and variations, Cell 139, 246-264 (2009). 18. Copits, BA et al., A photoswitchable GPCR-based opsin for presynaptic inhibition, Neuron 109, 1791-1809 e1711, doi:10.1016 / j.Neuron.2021.04.026 (2021). 19. Mahn, M. et al., Efficient optogenetic silencing of neurotransmitter release with a mosquito rhodopsin, Neuron 109, 1621-1635 e1628, doi:10.1016 / j.Neuron.2021.03.013 (2021). 20. Guler, AD et al., Melanopsin cells are the principal conduits for rod-cone input to non-image-forming vision, Nature 453, 102-105 (2008). 21. Hankins, MW, Peirson, SN & Foster, RG, Melanopsin: an exciting photopigment, Trends in neurosciences 31, 27-36 (2008). 22.Hattar, S., Liao, H.-W., Takao, M., Berson, DM & Yau, K.-W.,Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic photosensitivity, Science 295, 1065-1070 (2002). 23.Xue, T. et al.,Melanopsin signalling in mammalian iris and retina, Nature 479, 67-73 (2011). 24.Qiu, X. et al., Induction of photosensitivity by heterologous expression of melanopsin, Nature 433, 745-749 (2005). 25.Melyan, Z., Tarttelin, EE, Bellingham, J., Lucas, RJ & Hankins, MW, Addition of human melanopsin renders mammalian cells photoresponsive, Nature 433, 741-745, doi:10.1038 / nature03344 (2005). 26. Kojima, D. et al., UV-sensitive photoreceptor protein OPN5 in humans and mice, PLoS One 6, e26388, doi:10.1371 / journal.pone.0026388 (2011). 27. Yamashita, T. et al., Opn5 regulates the G protein G i Opn5 is a UV-sensitive bistable pigment that couples with G i subtype of G protein), Proc Natl Acad Sci USA 107, 22084-22089, doi:10.1073 / pnas.1012498107 (2010). 28.Zhang, KX et al.,Violet-light suppression of thermogenesis by opsin 5 hypothalamic neurons, Nature 585, 420-425, doi:10.1038 / s41586-020-2683-0 (2020). 29. Nakane, Y. et al., A mammalian neural tissue opsin (Opsin 5) is a deep brain photoreceptor in birds, Proceedings of the National Academy of Sciences 107, 15264-15268 (2010). 30.Nakane, Y., Shimmura, T., Abe, H. & Yoshimura, T., Intrinsic photosensitivity of a deep brain photoreceptor, Current Biology 24, R596-R597 (2014). 31. Rios, MN, Marchese, NA & Guido, ME, Expression of Non-visual Opsins Opn3 and Opn5 in the Developing Inner Retinal Cells of Birds. Light-Responses in Muller Glial Cells, Front Cell Neurosci 13, 376, doi:10.3389 / fncel.2019.00376 (2019). 32.Mederos, S. et al., Melanopsin for precise optogenetic activation of astrocyte‐neuron networks, Glia 67, 915-934 (2019). 33. Taniguchi, M. et al., A novel G from Chromobacterium sp. QS3666 q Structure of YM-254890, a Novel Gq / 11 Inhibitor from Chromobacterium sp. QS3666), Tetrahedron 59, 4533-4538, doi:10.1016 / s0040-4020(03)00680-x (2003). 34.Hartwig, J. et al., MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin, Nature 356, 618-622 (1992). 35.Zhang, F., Wang, L.-P., Boyden, ES & Deisseroth, K., Channelrhodopsin-2 and optical control of excitable cells, Nature methods 3, 785-792 (2006). 36. Lin, JY. A user's guide to channelrhodopsin variants: features, limitations and future developments. Experimental physiology 96, 19-25 (2011). 37. Gomez, JL et al., Chemogenetics revealed: DREADD occupancy and activation via converted clozapine, Science 357, 503-507 (2017). 38.Krashes, MJ et al., Rapid, reversible activation of AgRP neurons drives feeding behavior in mice, The Journal of clinical investigation 121, 1424-1428 (2011). 39. Rogan, SC, Roth, BL & Morrow, AL, Remote Control of Neuronal Signaling, Pharmacological Reviews 63, 291-315, doi:10.1124 / pr.110.003020 (2011). 40.Charles, AC, Merrill, JE, Dirksen, ER & Sandersont, MJ, Intercellular signaling in glial cells: calcium waves and oscillations in response to mechanical stimulation and glutamate, Neuron 6, 983-992 (1991). 41. Cornell-Bell, AH, Finkbeiner, SM, Cooper, MS & Smith, SJ, Glutamate induces calcium waves in cultured astrocytes: long-range glial signaling, Science 247, 470-473 (1990). 42. Zhang, F., Wang, LP, Boyden, ES & Deisseroth, K., Channelrhodopsin-2 and optical control of excitable cells, Nat Methods 3, 785-792, doi:10.1038 / nmeth936 (2006). 43. Davalos, D. et al., ATP mediates rapid microglial response to local brain injury in vivo, Nature neuroscience 8, 752-758 (2005). 44. Zhang, J.-M. et al., ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression, Neuron 40, 971-982 (2003). 45.Zhang, Z. et al., Regulated ATP release from astrocytes through lysosome exocytosis, Nature cell biology 9, 945-953 (2007). 46.Wu, Z. & Li, Y., New frontiers in probing the dynamics of purinergic transmitters in vivo, Neuroscience research 152, 35-43 (2020). 47. Wu, Z. et al., doi:10.1101 / 2021.02.24.432680 (2021). 48.Lawlor, PA, Bland, RJ, Mouravlev, A., Young, D. & During, MJ, Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates, Molecular therapy 17, 1692-1702 (2009). 49.Lee, Y., Messing, A., Su, M. & Brenner, M.,GFAP promoter elements required for region-specific and astrocyte-specific expression,Glia 56, 481-493 (2008). 50. Bal-Price, A., Moneer, Z. & Brown, GC, Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes, Glia 40, 312-323, doi:10.1002 / glia.10124 (2002). 51.Murakami, K., Nakamura, Y. & Yoneda, Y., Potentiation by ATP of lipopolysaccharide-stimulated nitric oxide production in cultured astrocytes, Neuroscience 117, 37-42 (2003). 52. Lezmy, J. et al., Astrocyte Ca(2+)-evoked ATP release regulates myelinated axon excitability and conduction speed, Science 374, eabh2858, doi:10.1126 / science.abh2858 (2021). 53.Tian, ​​L. et al., Imaging neural activity in worms, flies and mice with improved GCaMP calcium indicators, Nature methods 6, 875-881 (2009). 54. Jennings, JH, Rizzi, G., Stamatakis, AM, Ung, RL & Stuber, GD. The inhibitory circuit architecture of the lateral hypothalamus orchestrates feeding. Science 341, 1517-1521 (2013). 55. Stuber, GD & Wise, RA, Lateral hypothalamic circuits for feeding and reward, Nat Neurosci 19, 198-205, doi:10.1038 / nn.4220 (2016). 56. Li, Y. et al., Hypothalamic Circuits for Predation and Evasion, Neuron 97, 911-924 e915, doi:10.1016 / j.Neuron.2018.01.005 (2018). 57. Zhang, X. & van den Pol, A. N., Rapid binge-like eating and body weight gain driven by zona incerta GABA neuron activation, Science 356, 853-859, doi:10.1126 / science.aam7100 (2017). 58. Tsukamoto, H. & Terakita, A., Diversity and functional properties of bistable pigments, Photochemical & Photobiological Sciences 9, 1435-1443 (2010). 59.Ellis-Davies, GC, Caged compounds: photorelease technology for control of cellular chemistry and physiology, Nature methods 4, 619-628 (2007). 60. Adams, SR & Tsien, RY, Controlling cell chemistry with caged compounds, Annu Rev Physiol 55, 755-784, doi:10.1146 / annurev.ph.55.030193.003543 (1993). 61.Chen, T.-W. et al., Ultrasensitive fluorescent proteins for imaging neuronal activity, Nature 499, 295-300 (2013). 62. Jing, M. et al., An optimized acetylcholine sensor for monitoring in vivo cholinergic activity, Nature methods 17, 1139-1146 (2020). 63.Sun, F. et al., A genetically encoded fluorescent sensor enables rapid and specific detection of dopamine in flies, fish, and mice, Cell 174, 481-496. e419 (2018). 64.Wan, J. et al., A genetically encoded sensor for measuring serotonin dynamics, Nature Neuroscience 24, 746-752 (2021). 65. Zhao, Y. et al., Genetically encoded Ca 2+An expanded palette of genetically encoded Ca 2+ indicators), Science 333, 1888-1891 (2011). 66.Hochbaum, DR et al., All-optical electrophysiology in mammalian neurons using engineered microbial rhodopsins, Nat Methods 11, 825-833, doi:10.1038 / nmeth.3000 (2014). 67. Sahel, J.-A. et al., Partial recovery of visual function in a blind patient after optogenetic therapy, Nature Medicine, 1-7 (2021).

Claims

1. 1. An isolated light-sensitive opsin, comprising: G q An isolated light-sensitive opsin, characterized in that it is used for signal transduction and / or cell activation.

2. An isolated opsin, a homolog thereof, an ortholog thereof, a paralog thereof, a fragment thereof or a variant thereof, derived from an organism, q 2. The isolated opsin of claim 1, characterized in that it has signal transduction and / or cell activation activity.

3. has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a wild-type opsin, a homolog thereof, an ortholog thereof, a paralog thereof, a fragment thereof, or a variant thereof in said organism, q 2. The isolated opsin of claim 1, characterized in that it has signal transduction and / or cell activation activity.

4. An isolated opsin 5 (Opn5), a homologue thereof, an ortholog thereof, a paralog thereof, a fragment thereof or a variant thereof derived from an animal, q 2. The isolated opsin of claim 1, characterized in that it has signal transduction and / or cell activation activity.

5. has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a wild-type opsin 5 (Opn5), a homolog thereof, an ortholog thereof, a paralog thereof, a fragment thereof, or a variant thereof in the animal, q 5. The isolated opsin of claim 4, characterized in that it has signal transduction and / or cell activation activity.

6. The isolated opsin of claim 2 , wherein the organism is a vertebrate.

7. The vertebrate is a bird, a reptile, a fish, an amphibian or a mammal, Preferably, the animal is a bird, including, but not limited to, chicken, duck, goose, ostrich, emu, rhea, snipe, cassowary, turkey, quail, chicken, falconry, hawk, falcon, pigeon, parakeet, crowned cockatoo, macaw, parrot, passerine (e.g., songbird), jay, blackbird, finch, warbler, and sparrow; or Preferably, the animal is a reptile, including, but not limited to, lizards, snakes, alligators, sea turtles, crocodiles and tortoises; or Preferably, the animal is a fish, including, but not limited to, catfish, eels, sharks and swordfish; or 7. The isolated opsin of claim 6, wherein the animal is preferably an amphibian, including, but not limited to, toads, frogs, newts and salamanders.

8. The isolated Opsin 5 (Opn5) is an isolated wild-type Opsin 5 (Opn5) derived from chicken or a fragment or mutant thereof, q have signal transduction and / or cell activation activity, or The isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to wild-type opsin 5 (Opn5) derived from chicken, and q 5. The isolated opsin of claim 4, characterized in that it has signal transduction and / or cell activation activity.

9. The isolated Opsin 5 (Opn5) is an isolated wild-type Opsin 5 (Opn5) from a sea turtle or a fragment or mutant thereof, q have signal transduction and / or cell activation activity, or The isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to wild-type opsin 5 (Opn5) from a sea turtle, q 5. The isolated opsin of claim 4, characterized in that it has signal transduction and / or cell activation activity.

10. The isolated opsin 5 (Opn5) has the amino acid sequence shown in SEQ ID NO: 1 (cOpn5) or a fragment or variant thereof, q have signal transduction and / or cell activation activity, or The isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence shown in SEQ ID NO:1 (cOpn5), and q 5. The isolated opsin of claim 4, characterized in that it has signal transduction and / or cell activation activity.

11. The isolated opsin 5 (Opn5) has the amino acid sequence shown in SEQ ID NO:2 (tOpn5) or a fragment or variant thereof, q have signal transduction and / or cell activation activity, or The isolated opsin 5 (Opn5) has at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to the amino acid sequence shown in SEQ ID NO:2 (tOpn5), and q 5. The isolated opsin of claim 4, characterized in that it has signal transduction and / or cell activation activity.

12. 5. The isolated opsin of claim 4, wherein the light has a wavelength in the range of 360 to 520 nm, preferably 450 to 500, more preferably 460 to 480 nm, in particular 470 nm.

13. 1. An isolated nucleic acid comprising: An isolated nucleic acid, characterized in that it encodes an isolated opsin according to any one of claims 1 to 12.

14. A chimeric gene, A chimeric gene comprising the isolated nucleic acid sequence of claim 13, said nucleic acid sequence being operably linked to a suitable regulatory sequence.

15. A vector comprising: A vector, characterized in that it comprises the isolated nucleic acid according to claim 13 or the chimeric gene according to claim 14.

16. The vector according to claim 15, characterized in that the vector is a eukaryotic vector, a prokaryotic expression vector, a viral vector or a yeast vector.

17. The vector according to claim 16, characterized in that the vector is a herpes simplex virus vector, a vaccinia virus vector or an adenovirus vector, an adeno-associated virus vector, a retrovirus vector or an insect vector, preferably wherein the vector is a recombinant AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVS, AAVO or AAV10.

18. 18. The vector according to claim 17, characterized in that it is an expression vector or a gene therapy vector.

19. 1. An isolated cell or cell culture comprising: An isolated cell or cell culture, characterized in that it comprises an isolated nucleic acid according to claim 13, a chimeric gene according to claim 14 or a vector according to any one of claims 15 to 18.

20. G q A disease or condition mediated by signal transduction and / or cell activation, or q Use of the isolated opsin of any one of claims 1 to 12, the isolated nucleic acid of claim 13, the chimeric gene of claim 14, the vector of any one of claims 15 to 18 or the isolated cell or cell culture of claim 19 in the treatment of a disease or condition involving signal transduction and / or cell activation.

21. G in subjects q A disease or condition mediated by signal transduction and / or cell activation, or q 1. A method for treating a disease or condition involving signal transduction and / or cell activation, comprising: A method comprising administering an isolated opsin according to any one of claims 1 to 12, an isolated nucleic acid according to claim 13, a chimeric gene according to claim 14, a vector according to any one of claims 15 to 18, or an isolated cell or cell culture according to claim 19.

22. G q A disease or condition mediated by signal transduction and / or cell activation, or q Diseases or conditions involving signal transduction and / or cell activation include, but are not limited to, G q The method of claim 21, characterized in that the disease or condition includes, but is not limited to, diseases or conditions that benefit from signal transduction and / or cell activation, for example, diseases or conditions that benefit from astrocyte activation, potent ATP release or increased neuronal activity.

23. G q A disease or condition mediated by signal transduction and / or cell activation, or q The method according to claim 21, characterized in that the disease or condition involving signal transduction and / or cell activation includes, but is not limited to, diseases or conditions that benefit from activated cells such as pancreatic islet cells, immune cells, neuronal cells such as central neurons, astrocytes, glial cells, muscle cells, skeletal cells, endothelial cells, epithelial cells, nervous system cells, skin cells, lung cells, kidney cells and liver cells, cardiomyocytes or vascular endothelial cells.

24. 22. The method of claim 21, wherein the disease or condition is an autoimmune disease, a developmental disease, a metabolic disease, a psychiatric disease, a respiratory disease or a cardiovascular disease.

25. 22. A method according to claim 21, characterised in that the method comprises applying blue light in the wavelength range 360-550 nm, preferably 450-500 nm, more preferably 460-480 nm, in particular 470 nm.

26. 21. The method of claim 20, further comprising performing two-photon activation using light having a wavelength of > 920 nm.

Citation Information

Patent Citations

  • Optogenetic restoration of vision by light-sensitive GQ-coupled neuroopsin (opsin 5)

    JP2024545369A

  • Bistable type ii opsins and uses thereof

    WO2020188572A1

Cited By

  • Optogenetic restoration of vision by light-sensitive GQ-coupled neuroopsin (opsin 5)

    JP2024545369A